231 related articles for article (PubMed ID: 12578221)
1. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology.
Reifenberger G; Louis DN
J Neuropathol Exp Neurol; 2003 Feb; 62(2):111-26. PubMed ID: 12578221
[TBL] [Abstract][Full Text] [Related]
2. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetics of oligodendrogliomas: a model for improved clinical management in the field of neurooncology.
Nutt CL
Neurosurg Focus; 2005 Nov; 19(5):E2. PubMed ID: 16398466
[TBL] [Abstract][Full Text] [Related]
4. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
5. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.
Reifenberger J; Reifenberger G; Liu L; James CD; Wechsler W; Collins VP
Am J Pathol; 1994 Nov; 145(5):1175-90. PubMed ID: 7977648
[TBL] [Abstract][Full Text] [Related]
7. Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines.
Michaud K; de Tayrac M; D'Astous M; Duval C; Paquet C; Samassekou O; Gould PV; Saikali S
PLoS One; 2016; 11(12):e0168728. PubMed ID: 28030632
[TBL] [Abstract][Full Text] [Related]
8. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
Smith JS; Perry A; Borell TJ; Lee HK; O'Fallon J; Hosek SM; Kimmel D; Yates A; Burger PC; Scheithauer BW; Jenkins RB
J Clin Oncol; 2000 Feb; 18(3):636-45. PubMed ID: 10653879
[TBL] [Abstract][Full Text] [Related]
9. Oligodendrogliomas: impact of molecular genetics on treatment.
Hartmann C; von Deimling A
Neurol India; 2005 Jun; 53(2):140-8. PubMed ID: 16010049
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.
Bigner SH; Matthews MR; Rasheed BK; Wiltshire RN; Friedman HS; Friedman AH; Stenzel TT; Dawes DM; McLendon RE; Bigner DD
Am J Pathol; 1999 Aug; 155(2):375-86. PubMed ID: 10433931
[TBL] [Abstract][Full Text] [Related]
11. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors.
Shukla B; Agarwal S; Suri V; Pathak P; Sharma MC; Gupta D; Sharma BS; Suri A; Halder A; Sarkar C
Neurol India; 2009; 57(5):559-66. PubMed ID: 19934553
[TBL] [Abstract][Full Text] [Related]
12. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
Ohgaki H; Kleihues P
J Neuropathol Exp Neurol; 2005 Jun; 64(6):479-89. PubMed ID: 15977639
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of anaplastic oligodendroglial tumours.
Soffietti R
Expert Opin Pharmacother; 2004 Feb; 5(2):295-306. PubMed ID: 14996626
[TBL] [Abstract][Full Text] [Related]
14. Pathology and molecular genetics of oligodendroglial tumors.
Hartmann C; Mueller W; von Deimling A
J Mol Med (Berl); 2004 Oct; 82(10):638-55. PubMed ID: 15322700
[TBL] [Abstract][Full Text] [Related]
15. Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas.
Qu M; Olofsson T; Sigurdardottir S; You C; Kalimo H; Nistér M; Smits A; Ren ZP
Acta Neuropathol; 2007 Feb; 113(2):129-36. PubMed ID: 17031656
[TBL] [Abstract][Full Text] [Related]
16. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and management of oligodendroglioma.
van den Bent MJ
Semin Oncol; 2004 Oct; 31(5):645-52. PubMed ID: 15497117
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathology of oligodendroglial tumors.
Hartmann C; von Deimling A
Recent Results Cancer Res; 2009; 171():25-49. PubMed ID: 19322536
[TBL] [Abstract][Full Text] [Related]
19. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
Gupta M; Djalilvand A; Brat DJ
Am J Clin Pathol; 2005 Nov; 124(5):755-68. PubMed ID: 16203285
[TBL] [Abstract][Full Text] [Related]
20. [Diagnostic and prognostic roles of loss of CIC protein expression in oligodendroglial tumors].
Liu CC; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH; Piao YS
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):679-683. PubMed ID: 29050068
[No Abstract] [Full Text] [Related]
[Next] [New Search]
